All combined oral contraceptives can increase the risk of blood clots in the veins, potentially leading to phlebitis. However, clinical studies show that third- and fourth-generation pills—such as Mercilon, Minulet, Jasmine, and Qlaira (full list on ansm.sante.fr or has-sante.fr)—multiply this risk by four. In rare instances (about 4 cases per 10,000 users), it may progress to pulmonary embolism. Factors like smoking, age over 35, or bleeding disorders further elevate the risk. Serious complications can include venous or respiratory insufficiency, ankle edema, and varicose veins.
Risks are highest in the first year of use. After that, if you have no history of phlebitis or family clotting disorders, continuing may be appropriate—but only under medical supervision. Schedule regular check-ups with your doctor to monitor your health.
Opt for equally effective second-generation pills like Minidril, Adépal, or Perléane. These may cause side effects such as weight gain, acne, or breast tenderness, but third- and fourth-generation options offer no proven benefits in reducing them.
Sources: ANSM and Professor Bouvenot, President of the Transparency Commission and member of the Haute Autorité de Santé (HAS).
